Literature DB >> 22130119

PDE4: a novel target in the treatment of chronic obstructive pulmonary disease.

J M Michalski1, G Golden, J Ikari, S I Rennard.   

Abstract

Phosphodiesterases (PDEs) are important modulators of inflammation and wound healing. In this capacity, specific targeting of PDEs for the treatment of many diseases, including chronic obstructive pulmonary disease (COPD), has been investigated. Currently, treatment of COPD is suboptimal. PDE4 modulates the inflammatory response of the lung, and inhibition of PDE4 may be a novel, COPD-specific approach toward more effective treatment strategies. This review describes the state of PDE4-inhibitor therapy for use in COPD treatment.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22130119     DOI： 10.1038/clpt.2011.266

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  21 in total

1.  Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.

Authors:  Seiko Susuki-Miyata; Masanori Miyata; Byung-Cheol Lee; Haidong Xu; Hirofumi Kai; Chen Yan; Jian-Dong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 2.  Effect of roflumilast on chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Lu-Fei Shen; Xiao-Dong Lv; Wen-Yu Chen; Qi Yang; Zhi-Xian Fang; Wei-Fen Lu
Journal:  Ir J Med Sci       Date:  2018-02-03       Impact factor: 1.568

Review 3.  Genome-guided discovery of diverse natural products from Burkholderia sp.

Authors:  Xiangyang Liu; Yi-Qiang Cheng
Journal:  J Ind Microbiol Biotechnol       Date:  2013-11-09       Impact factor: 3.346

4.  Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment.

Authors:  Mamoudou Maiga; Nicole C Ammerman; Mariama C Maiga; Anatole Tounkara; Sophia Siddiqui; Michael Polis; Robert Murphy; William R Bishai
Journal:  J Infect Dis       Date:  2013-05-02       Impact factor: 5.226

5.  Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.

Authors:  Miriam Wittmann; Philip S Helliwell
Journal:  Dermatol Ther (Heidelb)       Date:  2013-04-27

6.  The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.

Authors:  Franziska M Konrad; Annette Bury; Martin A Schick; Kristian-Christos Ngamsri; Jörg Reutershan
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

7.  Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD.

Authors:  Kensei Komatsu; Ji-Yun Lee; Masanori Miyata; Jae Hyang Lim; Hirofumi Jono; Tomoaki Koga; Haidong Xu; Chen Yan; Hirofumi Kai; Jian-Dong Li
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

8.  Pyridazinone derivatives as potential anti-inflammatory agents: synthesis and biological evaluation as PDE4 inhibitors.

Authors:  Ingrid Allart-Simon; Aurélie Moniot; Nicolo Bisi; Miguel Ponce-Vargas; Sandra Audonnet; Marie Laronze-Cochard; Janos Sapi; Eric Hénon; Frédéric Velard; Stéphane Gérard
Journal:  RSC Med Chem       Date:  2021-03-01

9.  Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review).

Authors:  Ting Zhang; Xiangdong Zhou
Journal:  Exp Ther Med       Date:  2014-01-21       Impact factor: 2.447

10.  Multiple facets of cAMP signalling and physiological impact: cAMP compartmentalization in the lung.

Authors:  Anouk Oldenburger; Harm Maarsingh; Martina Schmidt
Journal:  Pharmaceuticals (Basel)       Date:  2012-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.